SG11201901873PA - Tablet compositions - Google Patents
Tablet compositionsInfo
- Publication number
- SG11201901873PA SG11201901873PA SG11201901873PA SG11201901873PA SG11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA SG 11201901873P A SG11201901873P A SG 11201901873PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- theta
- english
- september
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662384643P | 2016-09-07 | 2016-09-07 | |
| US201762535162P | 2017-07-20 | 2017-07-20 | |
| PCT/US2017/050202 WO2018048847A1 (en) | 2016-09-07 | 2017-09-06 | Tablet compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901873PA true SG11201901873PA (en) | 2019-03-28 |
Family
ID=59895401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901873PA SG11201901873PA (en) | 2016-09-07 | 2017-09-06 | Tablet compositions |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11389454B2 (https=) |
| EP (1) | EP3509570A1 (https=) |
| JP (2) | JP2019529534A (https=) |
| KR (1) | KR102498693B1 (https=) |
| CN (2) | CN109715143A (https=) |
| AU (1) | AU2017324844B2 (https=) |
| BR (1) | BR112019004356A2 (https=) |
| CA (1) | CA3036053A1 (https=) |
| CL (1) | CL2019000573A1 (https=) |
| CO (1) | CO2019002092A2 (https=) |
| EC (1) | ECSP19015828A (https=) |
| IL (1) | IL265126B2 (https=) |
| MX (1) | MX392941B (https=) |
| SG (1) | SG11201901873PA (https=) |
| WO (1) | WO2018048847A1 (https=) |
| ZA (1) | ZA201901321B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| MX392941B (es) * | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) * | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020239759A1 (en) * | 2019-05-27 | 2020-12-03 | Sandoz Ag | Amorphous enasidenib in a stabilized form |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| AR126195A1 (es) * | 2021-06-23 | 2023-09-27 | Blueprint Medicines Corp | Composiciones farmacéuticas de un inhibidor del receptor del factor de crecimiento epidérmico |
| WO2024008138A1 (zh) * | 2022-07-07 | 2024-01-11 | 正大天晴药业集团股份有限公司 | 1,3,5-三嗪衍生物的药物组合 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225964B1 (en) * | 1994-07-12 | 2008-01-28 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| AR016827A1 (es) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| IL159853A0 (en) * | 2001-07-17 | 2004-06-20 | Teva Pharma | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20070010466A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| WO2012027247A2 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| KR102316886B1 (ko) * | 2013-08-02 | 2021-10-19 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적 활성 화합물 및 이의 사용방법 |
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA3254279A1 (en) * | 2015-06-03 | 2025-03-18 | Triastek, Inc. | PHARMACEUTICAL FORMS AND RELATED USES |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| MX392941B (es) * | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
-
2017
- 2017-09-06 MX MX2019002697A patent/MX392941B/es unknown
- 2017-09-06 CA CA3036053A patent/CA3036053A1/en not_active Abandoned
- 2017-09-06 KR KR1020197006492A patent/KR102498693B1/ko active Active
- 2017-09-06 US US15/697,199 patent/US11389454B2/en active Active
- 2017-09-06 JP JP2019533300A patent/JP2019529534A/ja active Pending
- 2017-09-06 BR BR112019004356-0A patent/BR112019004356A2/pt not_active Application Discontinuation
- 2017-09-06 AU AU2017324844A patent/AU2017324844B2/en active Active
- 2017-09-06 WO PCT/US2017/050202 patent/WO2018048847A1/en not_active Ceased
- 2017-09-06 EP EP17768583.1A patent/EP3509570A1/en active Pending
- 2017-09-06 SG SG11201901873PA patent/SG11201901873PA/en unknown
- 2017-09-06 CN CN201780054265.1A patent/CN109715143A/zh active Pending
- 2017-09-06 CN CN202510669668.3A patent/CN120501712A/zh active Pending
- 2017-09-06 IL IL265126A patent/IL265126B2/en unknown
-
2019
- 2019-03-01 ZA ZA2019/01321A patent/ZA201901321B/en unknown
- 2019-03-05 CO CONC2019/0002092A patent/CO2019002092A2/es unknown
- 2019-03-06 EC ECSENADI201915828A patent/ECSP19015828A/es unknown
- 2019-03-06 CL CL2019000573A patent/CL2019000573A1/es unknown
-
2022
- 2022-06-21 US US17/845,807 patent/US20220323447A1/en not_active Abandoned
- 2022-09-22 JP JP2022150798A patent/JP7487270B2/ja active Active
-
2024
- 2024-06-17 US US18/745,080 patent/US20240335450A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019004356A2 (pt) | 2019-05-28 |
| JP2019529534A (ja) | 2019-10-17 |
| ZA201901321B (en) | 2023-12-20 |
| US20220323447A1 (en) | 2022-10-13 |
| IL265126B2 (en) | 2023-12-01 |
| IL265126A (https=) | 2019-04-30 |
| WO2018048847A1 (en) | 2018-03-15 |
| US11389454B2 (en) | 2022-07-19 |
| MX392941B (es) | 2025-03-24 |
| MX2019002697A (es) | 2019-10-04 |
| AU2017324844A1 (en) | 2019-03-21 |
| CN120501712A (zh) | 2025-08-19 |
| AU2017324844B2 (en) | 2023-05-11 |
| CA3036053A1 (en) | 2018-03-15 |
| CN109715143A (zh) | 2019-05-03 |
| ECSP19015828A (es) | 2019-03-29 |
| KR20190045199A (ko) | 2019-05-02 |
| KR102498693B1 (ko) | 2023-02-10 |
| JP7487270B2 (ja) | 2024-05-20 |
| IL265126B1 (en) | 2023-08-01 |
| CL2019000573A1 (es) | 2019-07-19 |
| NZ751112A (en) | 2024-03-22 |
| CO2019002092A2 (es) | 2019-05-31 |
| JP2022191265A (ja) | 2022-12-27 |
| US20180064715A1 (en) | 2018-03-08 |
| EP3509570A1 (en) | 2019-07-17 |
| US20240335450A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901873PA (en) | Tablet compositions | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201811396XA (en) | Extreme ultraviolet mask blank with multilayer absorber and method of manufacture | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| CA3015496A1 (en) | Voice control of a media playback system | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201903480TA (en) | Cell culture device system and methods of use thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |